Skip to main content

Table 2 Fasting biochemical characteristics of subjects according to their status

From: The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels

 

Controls

HeFH

HoFH

P

Total-C (mmol/L)

5.21 ± 0.92

8.55 ± 1.64*

10.54 ± 2.41*,**

<0.0001

LDL-C (mmol/L)

3.22 ± 0.85

6.89 ± 1.51*

8.88 ± 2.58*,**

<0.0001

HDL-C (mmol/L)

1.30 ± 0.31

1.03 ± 0.26*

1.02 ± 0.34*

<0.0001

Plasma triglycerides (mmol/L)

1.53 ± 0.71

1.52 ± 0.79

1.42 ± 0.56

0.9

Plasma apoB (mg/dL)

118.8 ± 50.9

207.1 ± 138.3*

601.3 ± 203.7*,**

<0.0001

Plasma apoB-48 (μg/mL)

3.03 ± 2.07

6.55 ± 4.24*

14.71 ± 4.36*,**

<0.0001

Plasma PCSK9 (ng/mL)

194.5 ± 65.9

324.9 ± 119.8*

642.6 ± 246.9*,**

<0.0001

  1. Data are listed as mean ± SD. All control and HeFH subjects were apoE3 homozygotes. HeFH heterozygotes for familial hypercholesterolemia, HoFH homozygotes for familial hypercholesterolemia, C cholesterol; apo: apolipoprotein, PCSK9 proprotein convertase subtilisin/kexin type 9
  2. * p < 0.05 vs. controls
  3. ** p < 0.05 vs. HeFH